Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway
© Allen et al.; licensee BioMed Central. 2015
Received: 16 January 2015
Accepted: 18 March 2015
Published: 1 May 2015
We previously reported the identification of ONC201/TIC10, a novel small molecule inducer of the human TRAIL gene that improves efficacy-limiting properties of recombinant TRAIL and is in clinical trials in advanced cancers based on its promising safety and antitumor efficacy in several preclinical models.
We performed a high throughput luciferase reporter screen using the NCI Diversity Set II to identify TRAIL-inducing compounds.
Small molecule-mediated induction of TRAIL reporter activity was relatively modest and the majority of the hit compounds induced low levels of TRAIL upregulation. Among the candidate TRAIL-inducing compounds, TIC9 and ONC201/TIC10 induced sustained TRAIL upregulation and apoptosis in tumor cells in vitro and in vivo. However, ONC201/TIC10 potentiated tumor cell death while sparing normal cells, unlike TIC9, and lacked genotoxicity in normal fibroblasts. Investigating the effects of TRAIL-inducing compounds on cell signaling pathways revealed that TIC9 and ONC201/TIC10, which are the most potent inducers of cell death, exclusively activate Foxo3a through inactivation of Akt/ERK to upregulate TRAIL and its pro-apoptotic death receptor DR5.
These studies reveal the selective activity of ONC201/TIC10 that led to its selection as a lead compound for this novel class of antitumor agents and suggest that ONC201/TIC10 is a unique inducer of the TRAIL pathway through its concomitant regulation of the TRAIL ligand and its death receptor DR5.
KeywordsONC201 TIC10 TRAIL TRAIL-inducing compound TNF-related apoptosis-inducing ligand DR5 Foxo3a Gene regulation
TRAIL is an endogenous protein that induces fulminant tumor-specific apoptosis through binding to death receptors DR4 or DR5 expressed in human tumor cells . TRAIL has received considerable attention since the gene was first cloned because of its therapeutic potential as a drug target for human cancer due to its ability to distinguish tumor from normal cells. TRAIL is naturally expressed in a several human tissues and membrane-bound TRAIL is also conditionally expressed in some immune cells following cytokine stimulation [2-6]. Through its expression in such cells, TRAIL plays a direct role in tumor suppression during immune surveillance though this anticancer mechanism is lost during the disease progression.
The ability of TRAIL to initiate apoptosis selectively in cancer cells has led to clinical trials with novel agents that engage the TRAIL pathway, which includes recombinant TRAIL and TRAIL-agonist antibodies that target DR4 or DR5 [7-13]. TRAIL-based experimental therapies have exhibited promising preclinical activity and safety in early phase clinical trials . Nevertheless, these investigational therapies did not prove sufficiently effective in clinical trials and the clinical development of recombinant TRAIL has been halted. While the reasons for clinical failure are not entirely clear, we and others have highlighted several undesirable drug properties that may hinder the efficacy of recombinant TRAIL such as serum half-life, stability, and/or biodistribution.
Several experimental efforts to improve the efficacy of TRAIL-targeted therapies have been reported. Recombinant TRAIL mutants that are remarkably more stable have been identified , as well as variants that contain leucine or isoleucine zippers to facilitate trimerization of the soluble ligand, since receptor-bound TRAIL is trimeric [16,17]. We previously reported a novel class of DR4-targeted proteins called DR4 Atrimers that are engineered to mimic the conformation of trimeric TRAIL bound to DR4 using a stable tetranectin scaffold . Mesenchymal stem cells overexpressing TRAIL have been described in preclinical studies that improve the biodistribution of TRAIL to enable activity against glioma since the available TRAIL-based therapies do not cross the blood–brain barrier . In vitro characterization and structure-activity relationships of small molecules that induce DR5 clustering and activation have also be reported .
TRAIL is a robust and selective tumor suppressor that offers itself as an attractive natural drug target to restore anti-tumor immunity. We hypothesized that upregulation of TRAIL expression by a small molecule would lead to a potent and novel anti-tumor mechanism by improving suboptimal drug properties of recombinant TRAIL. Regulation of the TRAIL gene has been described for several transcription factors , most of which are tumor suppressors such as p53 , and Foxo3a . We explicitly selected for TRAIL-inducing compounds that upregulate TRAIL gene transcription using a mechanism that does not rely on p53 due to its frequent inactivation in late stage cancers that causes resistance to many standard-of-care therapies . To identify small molecule p53-independent inducers of the human TRAIL gene we conducted a small molecule library screen using the NCI Diversity Set II. The screen was conducted in HCT116 cells lacking the Bax gene, which renders TRAIL resistance to allow for assay readout , and stably expressing a luciferase reporter of the human TRAIL gene promoter. Here we describe the preclinical studies that led to the selection of ONC201/TIC10 as the lead TRAIL-inducing compound that we previously reported as a novel and potent antitumor agent and has entered phase I clinical trials in advanced cancers .
Screening for small molecules that induce TRAIL gene promoter activity
TIC9 and ONC201/TIC10 induce TRAIL and apoptosis in vivo
Selection of ONC201/TIC10 as a lead TRAIL-inducing compound
Cytotoxic TRAIL-inducing compounds exclusively active Foxo3a
The magnitude and time points for kinetics of TRAIL induction observed in the screen for TRAIL-inducing compounds indicate that regulation of the TRAIL gene may be tightly controlled, perhaps due to its potent apoptotic potential. Chemical derivatives may be explored to improve TRAIL-inducing compounds in terms of potency and magnitude of TRAIL induction as well as potentially unveil structure-activity relationships. The observation that TIC9 and ONC201/TIC10 uniquely affect Akt- and ERK-mediated phosphorylation of Foxo3a is particularly interesting, given their exclusive ability to induce cancer cell death among the TRAIL-inducing compounds. While the two molecules are very diverse in structure and likely differ in other effects on cell signaling, this common effect suggests that Foxo3a may be an attractive transcriptional mechanism for inducing the TRAIL gene as an anticancer therapeutic mechanism.
While our first report of ONC201/TIC10 was in preparation, another report was published that described another novel class of small molecules that are capable of engaging the TRAIL death receptor pathway . Identified in other efforts aiming to find small molecule Smac mimetics, Wang et al. reported a small molecule, bioymifi, that induces the clustering of DR5 and activation of its downstream apoptotic signaling. This novel therapeutic approach holds promise a new class of TRAIL-based agents, though its spectrum of activity and in vivo activity will need to be evaluated in future studies.
TRAIL-inducing compounds are a novel class of TRAIL-based therapy that engage tumors and the host system to upregulate TRAIL and potentially sensitize tumor cells to its pro-apoptotic activity through dual death receptor and ligand induction, as seen with TIC9 and ONC201/TIC10. Several chemotherapies have been reported to induce DR5 as a mechanism of tumor cell sensitization to TRAIL-mediated apoptosis . Though p53 can also regulate the DR5 gene , both ONC201/TIC10  and brefledin A , which TIC9 is a prodrug of, possess p53-independent anti-cancer activity that suggests DR5 induction occurs through other transcription factors. p53-independent induction of DR5 in tumor cells has been confirmed for ONC201 . While both the TRAIL and DR5 gene promoters contain FOXO binding sites, future studies will explore the molecular mechanism of DR5 induction that may involve Foxo3a and/or other transcription factors. CHOP also has a binding site on the DR5 gene promoter that should be explored given recent reports of ONC201-induced activation of the integrated stress response .
These studies indicate that TIC9 was much more toxic to normal cells than ONC201/TIC10, which could be the result of a more pronounced DR5 induction by TIC9 that may carry over into normal cells unlike prior reports of ONC201/TIC10-induced DR5 in normal fibroblasts . Clinical trials with ONC201/TIC10 have recently commenced in advanced cancers to evaluate its safety as a monoagent. The safety features of ONC201/TIC10 that were a key selection criteria in this study offer a range of clinical opportunities where genotoxic and toxic therapies are intractable. Furthermore, combination therapy may be facilitated by the absence of overlapping toxicities and broad synergy with approved anti-cancer compounds that was recently reported for ONC201/TIC10 . Our studies cumulatively suggest that ONC201/TIC10 is a safe and effective antitumor agent that possesses a distinct mechanism of action that highlights the therapeutic potential of this novel class of anticancer drugs. This notion is further enhanced by its chemical structure, safety, and efficacy characteristics that are differentiated from other therapies used to treat cancer [32,33].
Cell culture and reagents
Cell lines were obtained from ATCC and cultured in ATCC-recommended media in a humidified incubator at 5% CO2 and 37°C. TICs were obtained from the NCI DTP, stored at −80°C, resuspended in DMSO, and maintained at −20°C for storage. The following compounds were ordered from the NCI DTP for follow up study: TIC1 (NSC 22819), TIC2 (NSC 96682), TIC4 (NSC 160319), TIC5 (NSC 320000), TIC6 (NSC 45741), TIC7 (NSC 64408), TIC8 (NSC 250826), TIC9 (NSC 656202), ONC201/TIC10 (NSC 350625).
Cell death assays
For Sub-G1 DNA content analysis, cells were trypsinized at the indicated time points and fixed in 80% ethanol at 4°C for a minimum of 30 minutes. Fixed cells were then stained with propidium iodide in the presence of RNase and analyzed on an Epics Elite flow cytometer (Beckman Coulter). Cell viability was assessed using Cell TiterGlo (Promega) in 96-well plates using the manufacturer’s protocol.
Western blot analysis
Cells were treated in log-phase growth, harvested by cell scraping, centrifuged, and lysed on ice for 2 hours with cell-lysis buffer. The supernatant was collected following centrifugation, and protein concentration was determined using the Bio-Rad protein assay (Bio-Rad Laboratories). Samples were electrophoresed under reducing conditions on NuPAGE 4-12% Bis-Tris gels (Invitrogen), transferred to PVDF, and blocked in 10% non-fat milk in TBST for 1 hour. Membranes were then incubated with primary antibodies obtained from Cell Signaling at 1:1000 in 2% non-fat milk in TBST overnight at 4°C. Membranes were washed in TBST, incubated with the appropriate HRP-conjugated secondary antibody (Thermo-Scientific) for 1 hour, washed in TBST, and visualized using ECL-Plus (Amersham) and X-Ray film (Thermo-Scientific).
In vivo studies
All animal experiments were conducted in accordance with the Institutional Animal Care and Use Committee. Athymic female nude mice (Charles River Laboratories) were inoculated with 5X106 of cancer cells in each rear flank as a 200 μL suspension of 1:1 Matrigel (BD):PBS. Treatment was administered by intraperitoneal injections at a total volume of 200 μL in DMSO. For tissue analysis, tissue was harvested from euthanized mice and fixed in 4% paraformaldehyde in PBS for 48 hours. Tissue was paraffin-embedded and sectioned by the Histology Core Facility at Penn State Hershey Medical Center. H&E staining (Daiko) and TUNEL staining (Millipore) were carried out according to the manufacturer’s protocols. TUNEL assessment was carried out by manual counting of positive cells in ten random fields of view. Bioluminescent imaging and immunohistochemistry for TRAIL expression was performed as previously described .
Cells were grown in chamber slides under sterile conditions as indicated. At end point, cells were fixed using BD Cytofix/Cytoperm according to the manufacturer’s protocol. Following fixation, cells were incubated with an anti-gamma H2AX antibody (Calbiochem DR1017) at 1:200 for 2 hours, rinsed, incubated with an Alexafluor 488 secondary antibody at 1:250 for 30 minutes, stained with Hoechst 33342 at 1 μg/mL for 5 minutes, rinsed, and imaged.
Death receptor 4
Death receptor 5
Extracellular signal-regulated kinases
Hematoxylin and eosin
National Cancer Institute
TNF-related apoptosis-inducing ligand
This work was supported by grants to W.S. El-Deiry.
- Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002;2:420–30.View ArticlePubMedGoogle Scholar
- Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673–82.View ArticlePubMedGoogle Scholar
- Fanger NA, Maliszewski CR, Schooley K, Griffith TS. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (Trail). J Exp Med. 1999;190:1155–64.View ArticlePubMed CentralPubMedGoogle Scholar
- Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fange NA. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med. 1999;189:1343–54.View ArticlePubMed CentralPubMedGoogle Scholar
- Kemp TJ, Moore JM, Griffith TS. Human B cells express functional TRAIL/Apo-2 ligand after CpG-containing oligodeoxynucleotide stimulation. J Immunol. 2004;173:892–9.View ArticlePubMedGoogle Scholar
- Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. Natural Killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and fas ligand by immature and mature primary human NK cells. J Exp Med. 1998;188:2375–80.View ArticlePubMed CentralPubMedGoogle Scholar
- Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer. 2008;61:82–90.View ArticlePubMedGoogle Scholar
- Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, et al. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res. 2010;16:1256–63.View ArticlePubMedGoogle Scholar
- Trarbach T, Moehler M, Heinemann V, Köhne CH, Przyborek M, Schulz C, et al. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer. 2010;102:506–12.View ArticlePubMed CentralPubMedGoogle Scholar
- Mom CH, Verweij J, Oldenhuis CN, Gietema JA, Fox NL, Miceli R, et al. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res. 2009;15:5584–90.View ArticlePubMedGoogle Scholar
- Leong S, Cohen RB, Gustafson DL, Langer CJ, Camidge DR, Padavic K, et al. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J Clin Oncol. 2009;27:4413–21.View ArticlePubMedGoogle Scholar
- Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R, et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res. 2007;13:6187–94.View ArticlePubMedGoogle Scholar
- Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, et al. Phase I pharmacokinetic and biologic correlative study of Mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor related apoptosis-inducing ligand receptor-1. J Clin Oncol. 2007;25:1390–6.View ArticlePubMedGoogle Scholar
- Abdulghani J, El-Deiry WS. TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets. 2010;14:1091–108.View ArticlePubMedGoogle Scholar
- Bremer E, Helfrich W. A Better TRAIL Variant for Tumor Cell-Specific Targeting? - Letter. Mol Cancer Ther. 2010;9:2853.View ArticlePubMedGoogle Scholar
- Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5:157–63.View ArticlePubMedGoogle Scholar
- Ganten TM, Koschny R, Sykora J, Schulze-Bergkamen H, Büchler P, Haas TL, et al. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res. 2006;12:2640–6.View ArticlePubMedGoogle Scholar
- Allen JE, Ferrini R, Dicker DT, Batzer G, Chen E, Oltean DI, et al. Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes. Mol Cancer Ther. 2012;11:2087–95.View ArticlePubMedGoogle Scholar
- Menon LG, Kelly K, Yang HW, Kim SK, Black PM, Carroll RS, et al. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells. 2009;27:2320–30.View ArticlePubMedGoogle Scholar
- Wang G, Wang X, Yu H, Wei S, Williams N, Holmes DL, et al. Small-molecule activation of the TRAIL receptor DR5 in human cancer cells. Nat Chem Biol. 2013;9:84–9.View ArticlePubMedGoogle Scholar
- Allen JE, El-Deiry WS. Regulation of the human TRAIL gene. Canc Biol Ther. 2012;13:1143–51.View ArticleGoogle Scholar
- Kuribayashi K, Krigsfeld G, Wang W, Xu J, Mayes PA, Dicker DT, et al. TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Canc Biol Ther. 2008;7:2034–8.View ArticleGoogle Scholar
- Ghaffari S, Jagani Z, Kitidis C, Lodish HF, Khosravi-Far R. Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. Proc Natl Acad Sci. 2003;100:6523–8.View ArticlePubMed CentralPubMedGoogle Scholar
- Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Investig. 1999;104:263–9.View ArticlePubMed CentralPubMedGoogle Scholar
- Burns TF, El-Deiry WS. Identification of Inhibitors of TRAIL-induced Death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J Biol Chem. 2001;276:37879–86.PubMedGoogle Scholar
- Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, et al. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction and potent anti-tumor effects. Sci Transl Med. 2013;5:171ra17.View ArticlePubMedGoogle Scholar
- Allen JE, El-Deiry WS. Oxaliplatin uses JNK to restore TRAIL sensitivity in cancer cells through Bcl-xL inactivation. Gastroenterology. 2011;141:430–4.View ArticlePubMedGoogle Scholar
- Wu GS, Burns TF, McDonald 3rd ER, Jiang W, Meng R, Krantz ID, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet. 2014;17:141–3.View ArticleGoogle Scholar
- Shao R-G, Shimizu T, Pommier Y, Brefeldin A. Is a potent inducer of apoptosis in human cancer cells independently of p53. Exp Cell Res. 2014;2:190–6.Google Scholar
- Ishizawa J, Kojima K, Chachad D, Ruvolo PP, Ruvolo VR, Jacamo R, et al. ONC201 induces p53-independent apoptosis and cell cycle arrest in hematological malignancies and leukemic stem/progenitor cells by inducing ER stress and mTOR inhibition. Blood. 2014;124:3122.Google Scholar
- Allen JE, Prabhu VV, Talekar M, van den Heuvel A, Lim B, Dicker DT, et al. Genetic and pharmacological screens converge in identifying FLIP, BCL2 and IAP proteins as key regulators of sensitivity to the TRAIL-inducing anti-cancer agent ONC201/TIC10. Cancer Res. 2015. [Epub ahead of print].
- Wagner J, Kline CL, Pottorf RS, Nallaganchu BR, Olson GL, Dicker DT, et al. The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity. Oncotarget. 2014;5:12728–37.PubMed CentralPubMedGoogle Scholar
- Prabhu VV, Talekar M, van den Heuvel A, Lim B, Dicker DT, et al. Small molecule ONC201/TIC10 targets chemotherapy-resistant colorectal cancer stem-like cells in an Akt/Foxo3a/TRAIL-dependent manner. Cancer Res. 2015. [Epub ahead of print].
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.